CureMatch Articles & News
Only a minority of clinical trials evaluating immunotherapeutic agents in 2019 used a biomarker to select patients for enrollment, a study found. The findings were reported at the virtual Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Preconference Programs (SITC 2020). Clinical trials evaluated were listed on ClinicalTrials.gov between January 1, 2019, and […]
Next-generation sequencing (NGS) has allowed the identification of novel potential targets for patients with cancer. Examples of successful matching of tumor molecular alterations to cognate drugs include: NTRK inhibitors larotrectinib and entrectinib in multiple solid tumors with NTRK fusions1,2, ROS1 inhibitors entrectinib and crizotinib in non-small cell lung cancer (NSCLC) with ROS1 alterations3,4, and the […]
PARIS and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ — WeHealth™ Digital Medicine, Servier Group’s e-health business unit, and CureMatch®, a leader in digital health precision medicine today announced that they have received CE Mark approval for Bionov™, their professional-use clinical decision support software…. read more See full article here
Precision medicine is revolutionizing cancer care. Dr. Razelle Kurzrock highlights how personalized treatments improve patient outcomes and quality of life. Plus, it’s enrollment season! Get the information you need for Medicare enrollment in this week’s conversation with Samantha Smith from the Patients Rising Concierge. And as November marks Lung Cancer Awareness Month, Terry and Dr. […]
Scientists from CureMatch and UCSD use pharmacophore-based drug design and a molecular docking technique to identify candidate protease inhibitors for COVID-19 SAN DIEGO, CA – April 15, 2020 – CureMatch, a digital health company focusing on personalized medicine and combination therapies, today announced that Chief Science Officer and Co-Founder, Dr. Igor Tsigelny, along with Dr. […]